In patients with CAPS, the concomitance of redox alterations (which accelerate the kinetics of IL-1β secretion) and gain-of-function NLRP3 mutations (which increase the amount of IL-1β secretion) may act in cooperation to worsen the CAPS phenotype. This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.